Although elevating epoxygenase products via sEH inhibition have been shown to be beneficial in a wide variety of animal models of cardiovascular disease, the mechanisms through which these effects are mediated are still largely unknown, although NF-κB and STAT3 have both been implicated. The gene discussed is NFKB1; the disease is cardiovascular disorder.